Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10344103 | 0.89 | KMT2A (0.73) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL9696121 | 0.89 | KMT2A (0.73) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL8198304 | 0.87 | KMT2A (0.77) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL10597179 | 0.87 | KMT2A (0.71) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL312287 | 0.85 | KMT2A (0.92) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL10600600 | 0.84 | KMT2A (0.67) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL9155739 | 0.84 | KMT2A (0.67) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL10708477 | 0.84 | LMNA (0.81) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL8788284 | 0.83 | KMT2A (0.76) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL28881004 | 0.83 | KMT2A (0.76) | KMT2ATDP1SLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | KMT2A 2645/4885TDP1 4680/4885SLC6A2 3456/4885 |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | ERBB2, EGFR, ERBB4 | KMT2A 2645/4885TDP1 4680/4885SLC6A2 3456/4885 |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | KMT2A 4207/4885TDP1 4063/4885SLC6A2 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.